Navigation Links
Isis Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Date:6/2/2011

CARLSBAD, Calif., June 2, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Jefferies' 2011 Global Healthcare Conference on Thursday, June 09, 2011 at 11:30 a.m. ET at the Grand Hyatt, New York.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... May 20, 2013  Whole-cell pertussis vaccines were more ... during a large recent outbreak, according to a new ... pertussis vaccines, also called DTwP, were available from the ... that ultimately led to the development of acellular pertussis ... 1990s, the United States had ...
(Date:5/18/2013)... YORK , May 18, 2013 ... law firm, is investigating potential securities fraud at ... AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... Company and its executives violated federal securities laws ... the Company,s Phase III drug trials for Tivopath ...
(Date:5/17/2013)... , May 17, 2013  Sorrento Therapeutics, ... its Fast-Track Advanced Technology Small Business Technology Transfer ... of Allergy and Infectious Diseases (NIAID), a division ... the development of novel human antibody therapeutics to ... or Staph) infections, including methicillin-resistant S. ...
Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4
... today reported one year,survival results from a Phase I/II ... in combination with dacarbazine in,patients with unresectable stage III ... cohort of patients in both the Phase I and,Phase ... the entire patient,set and a 22 month overall mean ...
... (NYSE:,AZN) today announced that the company has submitted ... U.S. Food and Drug,Administration (FDA) for once-daily SEROQUEL ... the treatment of manic,episodes associated with bipolar disorder ... disorder., The bipolar mania submission is based ...
Cached Medicine Technology:AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 2AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 3AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 4AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 2AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 3AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 4AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 5AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 6AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 7
(Date:5/20/2013)... Horizon NJ Health, New Jersey’s largest Medicaid ... has earned a Commendable Accreditation status from the ... is a wholly owned subsidiary of Horizon Blue Cross ... Plan Accreditation is a nationally recognized program that evaluates ... provide to their members. Health Plan Accreditation performance results ...
(Date:5/20/2013)... May 20, 2013 The American Society ... for Bright Pink®, the organization that empowers young women to ... end of 2012. Thanks to its members, ASCP raised more ... is involved in Relay for Life at the local level. ... he decided to donate. “I was made aware of the ...
(Date:5/20/2013)... New York (PRWEB) May 20, 2013 The ... new study has found that magnetic resonance imaging (MRI) can ... regardless of whether or not patients are experiencing symptoms. ... Journal of Bone & Joint Surgery, MRI detected synovitis ... In patients suffering symptoms due to mechanical causes, the detection ...
(Date:5/20/2013)... , , MONDAY, May 20 (HealthDay News) -- Boys who ... as likely to become obese adults as those who ... new 30-year study shows. Researchers found that men ... index (BMI) and obesity, even if they no longer ... well-off or poor, they tended toward obesity. ...
(Date:5/20/2013)... MONDAY, May 20 (HealthDay News) -- The older vaccine ... late 1990s is more effective than the current version ... who received four shots with the older vaccine -- ... old were significantly less likely to become infected with ... to children who received all of their immunizations with ...
Breaking Medicine News(10 mins):Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 2Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 2Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 4Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3Health News:Study: Older Whooping Cough Vaccine More Effective 2Health News:Study: Older Whooping Cough Vaccine More Effective 3
... is observed that breathing oxygen may cause some harm to ... beds of people //with severe lung or heart disease.Oxygen supports ... enough through the blood. But oxygen is often given inappropriately. ... 'breathe of life'. ,A study by researchers at New ...
... observed that approximately two thirds of teenage boys and ... suffer from at least// one psychiatric disorder. In ... evaluated by researchers before they were admitted to a ... interviewed the juvenile teens in order to track the ...
... Researchers have found that two types of scan are ... of ovarian cancer within the abdominal cavity. Positron emission ... of tumour tissue, while computed tomography (CT) is good ... School have found that combining the two detects ovarian ...
... an artificial disc to replace damaged spinal discs has successfully ... by discs of cartilage which serve as a cushion between ... two spinal bones may grind together, giving rise to acute ... disc is to remove it and fuse the two spinal ...
... with severe respiratory disease can walk further, and are less ... is key to pulmonary// rehabilitation in people who develop severe ... can walk in a fixed time and this helps them ... Ohio State University now report on the beneficial effect of ...
... coping style helps women to deal positively with breast cancer. ... difference in the fight against cancer. Researchers in the US ... stress, mental outlook and coping style are all relevant to ... ,They found that up to 44 per cent of ...
Cached Medicine News:
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
Medicine Products: